Emerging Company Profile
Kira: overcoming the complexities of complement
Emerging Company Profile: Kira debuts with Beddingfield as CEO, three programs slated to enter clinic over 18 months
China-U.S. biotech Kira debuts with three programs for complement-mediated diseases and Frederick Beddingfield as its CEO.
Cross-border biotech Kira is developing therapeutics for complement-mediated cancer and inflammatory and autoimmune diseases that address the mechanistic and PK challenges of targeting the complement pathway.
Kira Pharmaceuticals Ltd. was founded in 2017 by Chairman, President and